Rxo (RXO) Total Non-Current Liabilities (2021 - 2026)

Rxo (RXO) has reported Total Non-Current Liabilities for 6 consecutive years, with $711.0 million the latest figure, recorded in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $711.0 million, down 5.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $711.0 million (down 5.58% YoY), and the FY2025 annual result was $698.0 million, down 5.29% from the prior year.
• Total Non-Current Liabilities was $711.0 million for Q1 2026 at Rxo, up from $698.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $793.0 million in Q3 2024 and troughed at $205.0 million in Q3 2022.
• Average Total Non-Current Liabilities over 5 years is $632.9 million, with a median of $628.0 million recorded in 2023.
• Year-over-year, Total Non-Current Liabilities surged 241.21% in 2022 and slipped 11.59% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $621.0 million in 2022, then dropped by 11.59% to $549.0 million in 2023, then jumped by 34.24% to $737.0 million in 2024, then retreated by 5.29% to $698.0 million in 2025, then advanced by 1.86% to $711.0 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $711.0 million in Q1 2026, $698.0 million in Q4 2025, and $714.0 million in Q3 2025.